AmerisourceBergen Corporation Pharmaceutical Distributor 412 1st Street SE, Suite 200 WASHINGTON, DC 20003 USA |
Lobbying on the following issues:
MEDICARE/MEDICAID PHARMACY Medicare Prompt Pay Discount Exclusion - legislation to ensure more appropriate general payment amount for drugs and biologics under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price (ASP). ASP generally (in the context of deficit reduction). Policies to exclude cancer drugs from the sequestration cuts. Removal of Safe Harbor protection for rebates to plans of PBMs involving prescription pharmaceuticals and creation of new Safe Harbor protection. International Pricing Index Model. Competitive Acquisition Program. S. 2543 The Prescription Drug Pricing Reduction Act of 2019. Medicare Part B Biosimilar Reimbursement. Proposed modifications to the existing definition of distributor bona fide service fees in Medicare Part B. - Legislation to provide for coverage under Medicare program of pharmacist services. Medication therapy management. S. 988 and H.R. 803, legislation to prohibit prescription drug plan sponsors and MAPD organizations under Medicare program from retroactively reducing payment on clean claims submitted by pharmacies. Pharmaceutical compounding and the implementation of the Drug Quality Security Act; FDA implementation of Section 503B of the Food, Drug, and Cosmetic Act; House and Senate Agriculture, FDA, and related agency Appropriations bills; H.R. 1959, Preserving Patient Access to Compounded Medications. Prescription drug importation. H.R. 1034 and S. 640, Phair Pricing Act. DEA Order Clearinghouse Act (H.R. 6600, S. 3282 - 115th Congress). H.R. 1607 - Fairness to Pet Owners Act of 2019. S.724 and H.R. 1614 John S. McCain Opioid Addiction Prevent Act. - Lobbyists: NORTON, RITA ETALLAMY, BRADFORDMITCHELL, VIVIENNE STAFFORDO'Sullivan, Ashley Rose
Foreign Entities: Foreign Entity Name : Booking Holdings Inc. (U.S. company, owner of Booking.com Holding B.V.)Country : USAContribution : $0 - Foreign Entity Name : Booking.com Int'l Services B.V. (Owner of Booking.com Consulting Services (USA) Inc.)Country : NETHERLANDSContribution : $0 - Foreign Entity Name : Booking.com Holding B.V. (Owner of Booking.com Int'l Services B.V.)Country : NETHERLANDSContribution : $0 - |
Lobbying on the following issues:
MEDICARE/MEDICAID PHARMACY Medicare Prompt Pay Discount Exclusion - legislation to ensure more appropriate general payment amount for drugs and biologics under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price (ASP). ASP generally (in the context of deficit reduction). Policies to exclude cancer drugs from the sequestration cuts. Removal of Safe Harbor protection for rebates to plans of PBMs involving prescription pharmaceuticals and creation of new Safe Harbor protection. International Pricing Index Model. Competitive Acquisition Program. - Legislation to provide for coverage under Medicare program of pharmacist services. Medication therapy management. S. 988 and H.R. 803, legislation to prohibit prescription drug plan sponsors and MAPD organizations under Medicare program from retroactively reducing payment on clean claims submitted by pharmacies. Pharmaceutical compounding and the implementation of the Drug Quality Security Act; FDA implementation of Section 503B of the Food, Drug, and Cosmetic Act; House and Senate Agriculture, FDA, and related agency Appropriations bills; H.R. 1959, Preserving Patient Access to Compounded Medications. Prescription drug importation. H.R. 1034, Phair Pricing Act. DEA Order Clearinghouse Act (H.R. 6600, S. 3282 - 115th Congress). H.R. 1607 - Fairness to Pet Owners Act of 2019. - Lobbyists: NORTON, RITA ETALLAMY, BRADFORDMITCHELL, VIVIENNE STAFFORD Held the following Government positions Staff Assistant, U.S. Senator Elizabeth Dole (2008) Staff Assistant, U.S. Senator Elizabeth Dole (2008)O'Sullivan, Ashley Rose
Foreign Entities: Foreign Entity Name: Accenture PlcCountry : IRELANDContribution : $0 |
Lobbying on the following issues:
PHARMACY MEDICARE/MEDICAID Legislation to provide for coverage under Medicare program of pharmacist services. Medication therapy management. S. 988 and H.R. 803, legislation to prohibit prescription drug plan sponsors and MAPD organizations under Medicare program from retroactively reducing payment on clean claims submitted by pharmacies. Pharmaceutical compounding and the implementation of the Drug Quality Security Act; FDA implementation of Section 503B of the Food, Drug, and Cosmetic Act; House and Senate Agriculture, FDA, and related agency Appropriations bills; H.R. 1959, Preserving Patient Access to Compounded Medications. Prescription drug importation. H.R. 1034 and S. 640, Phair Pricing Act. DEA Order Clearinghouse Act (H.R. 6600, S. 3282 - 115th Congress). H.R. 1607 - Fairness to Pet Owners Act of 2019. S.724 and H.R. 1614 John S. McCain Opioid Addiction Prevent Act. Issues related to drug shortages. Coronavirus Aid, Relief and Economic Security Act (CARES Act) - Medicare Prompt Pay Discount Exclusion - legislation to ensure more appropriate general payment amount for drugs and biologics under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price (ASP). ASP generally (in the context of deficit reduction). Policies to exclude cancer drugs from the sequestration cuts. Removal of Safe Harbor protection for rebates to plans of PBMs involving prescription pharmaceuticals and creation of new Safe Harbor protection. International Pricing Index Model. Competitive Acquisition Program. S. 2543 The Prescription Drug Pricing Reduction Act of 2019. Medicare Part B Biosimilar Reimbursement. Proposed modifications to the existing definition of distributor bona fide service fees in Medicare Part B. Coronavirus Aid, Relief and Economic Security Act (CARES Act) - Lobbyists: NORTON, RITA ETALLAMY, BRADFORDMITCHELL, VIVIENNE STAFFORDO'Sullivan, Ashley Rose
Foreign Entities: Foreign Entity Name : Imperial Tobacco Holdings (2007) LimitedCountry : UNITED KINGDOMContribution : $0 - Foreign Entity Name : Imperial Brands PLCCountry : UNITED KINGDOMContribution : $0 - Foreign Entity Name : Imperial Brands Holdings International B.V.Country : NETHERLANDSContribution : $0 - Foreign Entity Name : Imperial Tobacco Holdings (1) LimitedCountry : UNITED KINGDOMContribution : $0 - Foreign Entity Name : Imperial Tobacco U.S. Holdings B.V.Country : NETHERLANDSContribution : $0 - Foreign Entity Name : Imperial Tobacco Holdings (Netherlands) B.V.Country : NETHERLANDSContribution : $0 - Foreign Entity Name : Imperial Tobacco Holdings LimitedCountry : UNITED KINGDOMContribution : $0 - Foreign Entity Name : Imperial Tobacco Overseas Holdings (4) LimitedCountry : UNITED KINGDOMContribution : $0 - Foreign Entity Name : Imperial Tobacco Overseas Holdings Limited Dutch BranchCountry : NETHERLANDSContribution : $0 - Foreign Entity Name : Imperial Tobacco Overseas LimitedCountry : UNITED KINGDOMContribution : $0 - Foreign Entity Name : Fontem Ventures B.V.Country : |
Lobbying on the following issues:
PHARMACY MEDICARE/MEDICAID Legislation to provide for coverage under Medicare program of pharmacist services. Medication therapy management. S. 988 and H.R. 803, legislation to prohibit prescription drug plan sponsors and MAPD organizations under Medicare program from retroactively reducing payment on clean claims submitted by pharmacies. Pharmaceutical compounding and the implementation of the Drug Quality Security Act; FDA implementation of Section 503B of the Food, Drug, and Cosmetic Act; House and Senate Agriculture, FDA, and related agency Appropriations bills; H.R. 1959, Preserving Patient Access to Compounded Medications. Prescription drug importation. H.R. 1034 and S. 640, Phair Pricing Act. DEA Order Clearinghouse Act (H.R. 6600, S. 3282 - 115th Congress). H.R. 1607 - Fairness to Pet Owners Act of 2019. S.724 and H.R. 1614 John S. McCain Opioid Addiction Prevent Act. - Medicare Prompt Pay Discount Exclusion - legislation to ensure more appropriate general payment amount for drugs and biologics under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price (ASP). ASP generally (in the context of deficit reduction). Policies to exclude cancer drugs from the sequestration cuts. Removal of Safe Harbor protection for rebates to plans of PBMs involving prescription pharmaceuticals and creation of new Safe Harbor protection. International Pricing Index Model. Competitive Acquisition Program. S. 2543 The Prescription Drug Pricing Reduction Act of 2019. Medicare Part B Biosimilar Reimbursement. Proposed modifications to the existing definition of distributor bona fide service fees in Medicare Part B. - Lobbyists: NORTON, RITA ETALLAMY, BRADFORDMITCHELL, VIVIENNE STAFFORDO'Sullivan, Ashley Rose
Foreign Entities: Foreign Entity Name: SNCFCountry : FRANCEContribution : $0 |
Lobbying on the following issues:
PHARMACY MEDICARE/MEDICAID Legislation to provide for coverage under Medicare program of pharmacist services. Medication therapy management. S. 988 and H.R. 803, legislation to prohibit prescription drug plan sponsors and MAPD organizations under Medicare program from retroactively reducing payment on clean claims submitted by pharmacies. Pharmaceutical compounding and the implementation of the Drug Quality Security Act; FDA implementation of Section 503B of the Food, Drug, and Cosmetic Act; House and Senate Agriculture, FDA, and related agency Appropriations bills; H.R. 1959, Preserving Patient Access to Compounded Medications. Prescription drug importation. H.R. 1034, Phair Pricing Act. DEA Order Clearinghouse Act (H.R. 6600, S. 3282 - 115th Congress). H.R. 1607 - Fairness to Pet Owners Act of 2019. S.724 John S. McCain Opioid Addiction Prevent Act. - Medicare Prompt Pay Discount Exclusion - legislation to ensure more appropriate general payment amount for drugs and biologics under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price (ASP). ASP generally (in the context of deficit reduction). Policies to exclude cancer drugs from the sequestration cuts. Removal of Safe Harbor protection for rebates to plans of PBMs involving prescription pharmaceuticals and creation of new Safe Harbor protection. International Pricing Index Model. Competitive Acquisition Program. Medicare Part B Biosimilar Reimbursement. - Lobbyists: NORTON, RITA ETALLAMY, BRADFORDMITCHELL, VIVIENNE STAFFORD Held the following Government positions Staff Assistant, U.S. Senator Elizabeth Dole (2008) Staff Assistant, U.S. Senator Elizabeth Dole (2008)O'Sullivan, Ashley Rose
Foreign Entities: Foreign Entity Name : Fiat Chrysler Automobiles N.V.Country : UNITED KINGDOMContribution : $0 - Foreign Entity Name : FCA North America Holdings, LLCCountry : USAContribution : $0 - |
Lobbying on the following issues:
AGRICULTURE PHARMACY MEDICARE/MEDICAID Implementation of the Veterinarian Food Directive; Antimicrobial Resistance. - S. 483 (114th Congress) legislation to prevent and reduce prescription drug abuse. H.R. 592 & S. 109, provide for coverage under Medicare program of pharmacist services. Medication Therapy Management. H.R. 1038 and S. 413, legislation to prohibit prescription drug plan sponsors and MAPD organizations under Medicare program from retroactively reducing payment on clean claims submitted by pharmacies. Pharmaceutical compounding and the implementation of Drug Quality Security Act; FDA implementation of Section 503B of the Food, Drug, and Cosmetic Act; House & Senate Agriculture, FDA & Related Agency Appropriations bills; H.R. 2871, Preserving Patient Access to Compounded Medications Act of 2017. Prescription Drug Importation including S. 771 and H.R. 1776, the Improving Access to Affordable Prescription Drugs Act and S.469, the Affordable and Safe Prescription Drug Importation Act. E-Prescribing bills including H.R. 3528 and S. 2460, the Every Prescription Conveyed Securely (EPCS) Act. H.R. 5958, Phair Pricing Act of 2018. HHS Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs. S. 3282 and H.R. 6600, the DEA Order Clearinghouse Act of 2018. H.R. 6, SUPPORT for Patients and Communities Act. - H.R. 1920 (Medicare Prompt Pay Discount Exclusion), legislation to ensure more appropriate general payment amount for drugs and biological under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. Average Sales Price (ASP) generally (in the context of Deficit Reduction). Policies to exclude cancer drugs from the sequestration cuts. Removal Of Safe Harbor Protection for Rebates to Plans or PBMs Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection. International Pricing Index Model. Competitive Acquisition Program. - Lobbyists: NORTON, RITA ETALLAMY, BRADFORDMITCHELL, VIVIENNE STAFFORD Held the following Government positions Staff Assistant, U.S. Senator Elizabeth Dole (2008) Staff Assistant, U.S. Senator Elizabeth Dole (2008) Staff Assistant, U.S. Senator Elizabeth Dole (2008)O'Sullivan, Ashley Rose
Foreign Entities: Foreign Entity Name: CACIFCountry : GUATEMALAContribution : $30,000 |
Money Spent:
Amount | Client | Government Entities |
---|
$775,000
Jan 21, 2020
FOURTH QUARTER REPORT
AMERISOURCEBERGEN CORPORATION
HOUSE OF REPRESENTATIVESWhite House OfficeHealth & Human Services, Dept of (HHS)Food & Drug Administration (FDA)Centers For Medicare and Medicaid Services (CMS)SENATE
$630,000
Apr 22, 2019
FIRST QUARTER REPORT
AMERISOURCEBERGEN CORPORATION
HOUSE OF REPRESENTATIVESWhite House OfficeHealth & Human Services, Dept of (HHS)Food & Drug Administration (FDA)Centers For Medicare and Medicaid Services (CMS)SENATE
$560,000
Apr 20, 2020
FIRST QUARTER REPORT
AMERISOURCEBERGEN CORPORATION
HOUSE OF REPRESENTATIVESWhite House OfficeHealth & Human Services, Dept of (HHS)Food & Drug Administration (FDA)Centers For Medicare and Medicaid Services (CMS)SENATE
$530,000
Oct 21, 2019
THIRD QUARTER REPORT
AMERISOURCEBERGEN CORPORATION
HOUSE OF REPRESENTATIVESWhite House OfficeHealth & Human Services, Dept of (HHS)Food & Drug Administration (FDA)Centers For Medicare and Medicaid Services (CMS)SENATE
$510,000
Jul 22, 2019
SECOND QUARTER REPORT
AMERISOURCEBERGEN CORPORATION
HOUSE OF REPRESENTATIVESWhite House OfficeHealth & Human Services, Dept of (HHS)Food & Drug Administration (FDA)Centers For Medicare and Medicaid Services (CMS)SENATE
$450,000
Jan 22, 2019
FOURTH QUARTER REPORT
AMERISOURCEBERGEN CORPORATION
HOUSE OF REPRESENTATIVESWhite House OfficeHealth & Human Services, Dept of (HHS)Food & Drug Administration (FDA)Centers For Medicare and Medicaid Services (CMS)SENATE